Recent progress in characterization of NSCLC by molecular typing, especially in adenocarcinomas of the lung, have brought new investigation of therapeutic agents that target dominant oncogenic mutations, such as epidermal growth factor receptor (EGFR)-targeted therapies, which have showed improved response rates in patients with NSCLC (Shigematsu et al., 2005). Here, EGFR is linked to non-small cell lung carcinoma.